TORONTO, Canada (AP/WJZ)– Clinical trials for an Ebola vaccine will be tested on humans in a Maryland laboratory Monday.
The experimental Canadian-made vaccine showed promise in tests on primates.READ MORE: Inside The Case: How Federal Agents Built Their Investigation Into Catherine Pugh's 'Healthy Holly' Book Scandal
READ MORE ON EBOLA VACCINES: Baltimore Doctor In Mali Administering First Trials Of Ebola Vaccine |UMd. Plays Role In Ebola Vaccine Test In Africa
The vaccine will be tested on healthy individuals Monday to see how well it works, whether there are side effects and what the proper dosage is, Canadian Health Minister Rona Ambrose said.READ MORE: 3 Dead In Domestic-Related Laurel Shooting, Child Hospitalized
Studies in primates have shown this vaccine works both to prevent infection when given before exposure and to increase survival chances when given quickly after exposure.
A small Iowa-based company called NewLink Genetics holds the license for the vaccine and the trials are set to begin in a lab in Maryland. Ambrose said the results are expected in December.
NewLink said earlier this month that at least five clinical trials involving the vaccine, known as VSV-EBOV, would soon be underway in the United States, Germany, Switzerland and in an unnamed African country that is not battling Ebola.MORE NEWS: Police Continue To Investigate Woodlawn Shooter's Background, Neighbors Say They Have Been Complaining For Years
(Copyright 2013 by The Associated Press. All Rights Reserved.)